The global landscape of vaccine development, profoundly reshaped by the COVID-19 pandemic, is witnessing a significant paradigm shift with the emergence of a novel DNA origami nanotechnology platform named DoriVac. This innovative approach, developed by a multidisciplinary consortium from the Wyss Institute at Harvard University, Dana-Farber Cancer Institute (DFCI), and partner institutions, presents a compelling alternative to messenger RNA (mRNA) vaccines, promising enhanced stability, simplified manufacturing, and broader accessibility for combating infectious diseases worldwide. Detailed findings published in Nature Biomedical Engineering highlight DoriVac’s ability to elicit strong and comprehensive immune responses in both preclinical mouse models and advanced human organ-on-a-chip systems, positioning it as a potentially transformative tool in future pandemic preparedness and global health strategies. The mRNA Revolution and Its Unforeseen Challenges The COVID-19 pandemic irrevocably propelled messenger RNA (mRNA) vaccines into the international spotlight, marking a historic acceleration in vaccine science. Following an unprecedented clinical trial phase, the first COVID-19 mRNA vaccine was administered on December 8, 2020, ushering in a new era of rapid vaccine development. The impact was profound; researchers subsequently estimated through sophisticated modeling that these pioneering vaccines averted at least 14.4 million deaths globally within their inaugural year alone, fundamentally altering the trajectory of the pandemic and underscoring the immense potential of genetic vaccine technologies. This extraordinary success immediately spurred scientists worldwide to extend the application of mRNA technology to a wider array of infectious diseases. Currently, a robust pipeline of mRNA vaccine candidates is undergoing clinical trials, targeting a diverse spectrum of pathogens including influenza virus, Respiratory Syncytial Virus (RSV), HIV, Zika, Epstein-Barr virus, and even tuberculosis bacteria. This rapid expansion reflects the inherent advantages of mRNA platforms, such as their speed of development and adaptability. However, the intensive real-world deployment and ongoing studies of COVID-19 mRNA vaccines have also illuminated critical limitations, emphasizing the urgent need for complementary or alternative vaccine strategies. While highly effective, the immune protection conferred by COVID-19 mRNA vaccines can exhibit considerable variability among individuals, and, crucially, it does not confer indefinite immunity. This challenge is further exacerbated by the relentless evolutionary pressure on SARS-CoV-2, which continually generates new variants capable of partially evading existing immune defenses, necessitating frequent vaccine updates and booster campaigns. Beyond these immunological complexities, practical hurdles associated with mRNA vaccine deployment have become evident. The manufacturing process for mRNA vaccines is inherently intricate, requiring specialized facilities and sophisticated biochemical control mechanisms. The precise packaging of mRNA molecules into lipid nanoparticles (LNPs), critical for their delivery and efficacy, remains a complex and expensive endeavor. Furthermore, a significant logistical constraint is the requirement for stringent ultra-cold storage, often at temperatures as low as -70°C, which poses substantial challenges for distribution, particularly in regions with limited infrastructure or in developing countries. There are also ongoing investigations into potential unintended off-target effects associated with LNP delivery. Overcoming these multifaceted limitations is paramount for bolstering global resilience against future infectious disease threats and ensuring equitable access to life-saving vaccines. DoriVac: A Precision-Engineered Nanotechnology Platform In response to these pressing challenges, a collaborative, multidisciplinary team comprising experts from the Wyss Institute at Harvard University, Dana-Farber Cancer Institute (DFCI), and other partner institutions embarked on exploring an entirely distinct approach. Their work centered on a novel DNA origami nanotechnology platform, aptly named DoriVac. This platform is distinguished by its unique dual functionality, operating effectively as both a vaccine and an integrated adjuvant, a component designed to enhance the immune response. At its core, DoriVac leverages the principles of DNA nanotechnology, a field that precisely engineers DNA molecules to self-assemble into complex, predefined nanoscale structures. In 2024, Dr. William Shih’s team at the Wyss Institute and Dana-Farber initially introduced DoriVac as a versatile, DNA nanotechnology-based vaccine platform with broad potential, initially focusing on cancer applications. Dr. Yang (Claire) Zeng, M.D., Ph.D., who spearheaded much of this effort, demonstrated DoriVac’s remarkable capability to precisely present immune-stimulating adjuvant molecules to cells at the nanoscale, a level of control previously unattainable with conventional vaccine formulations. The structural elegance of DoriVac vaccines lies in their construction from tiny, self-assembling square DNA nanostructures. These structures are meticulously designed to present different functional components on opposing faces. One side is engineered to display adjuvant molecules, arranged at carefully controlled nanometer distances, which are crucial for stimulating a robust immune response. The opposite side presents selected antigens—peptides or proteins derived from pathogens or tumor cells—that serve as the targets for immune recognition. This precise spatial arrangement of adjuvant and antigen is hypothesized to optimize their interaction with immune cells, leading to a more potent and targeted response. Pivoting to Infectious Diseases: A Strategic Response to the Pandemic While the initial development of the DoriVac platform was geared towards oncology, the persistent and global impact of the COVID-19 pandemic prompted a strategic reevaluation of its potential applications. "While we were developing the platform for cancer applications, the COVID-19 pandemic was still moving with full force. So, the question quickly arose whether DoriVac’s superior adjuvant activity could also be leveraged in infectious disease settings," stated Dr. Zeng, who is a first and co-corresponding author on the new study and has since co-founded and assumed the role of CEO/CTO of DoriNano, a company dedicated to translating this innovative technology into clinical applications. To explore this promising avenue, Dr. Zeng and co-first author Dr. Olivia Young, a former graduate student in Dr. Shih’s group, initiated a critical collaboration with Dr. Donald Ingber’s team at the Wyss Institute. Dr. Ingber’s group is renowned for its pioneering work in antiviral innovation, employing advanced AI-driven and multiomics approaches alongside sophisticated microfluidic human Organ Chip systems. Together with co-first author Dr. Longlong Si, a former postdoctoral researcher in Dr. Ingber’s lab, the researchers meticulously designed DoriVac vaccines specifically targeting a conserved peptide region (HR2) found in the spike proteins of several highly pathogenic viruses, including SARS-CoV-2, HIV, and Ebola. The selection of the HR2 peptide as a conserved antigen is a strategic choice, aiming to induce broad and potentially cross-protective immunity against evolving viral strains. Preclinical Efficacy: Robust Immune Activation in Mouse Models The initial evaluation of these DoriVac vaccines in mouse models yielded highly encouraging results, demonstrating their capacity to provoke potent and comprehensive immune responses. Dr. Zeng elaborated on these findings: "Our analysis of the immune responses provoked by these first DoriVac vaccines in mice led to several encouraging observations, including significantly greater and broader activation of humoral and cellular immunity across a range of relevant immune cell types than what the origami-free antigens and adjuvants could produce." Specifically, the DoriVac SARS-CoV-2 HR2 vaccine triggered strong antibody-driven (humoral) and T cell-driven (cellular) activity. Detailed immunological assays revealed substantial increases in the numbers of critical immune cells: antibody-producing B cells, activated antigen-presenting dendritic cells (DCs), and antigen-specific memory and cytotoxic T cell types. These cell populations are indispensable for establishing both immediate protection and long-term immunological memory, which is vital for sustained defense against reinfection. The particularly pronounced increases observed for the SARS-CoV-2 HR2 DoriVac vaccine underscored its potential to address a significant public health need. This comprehensive activation of both arms of the adaptive immune system suggests DoriVac’s capability to mount a multi-pronged attack against pathogens, offering potentially more durable and broad-spectrum protection. Translational Leap: From Mouse to Human Organ Chips A persistent hurdle in vaccine development lies in the translational gap between preclinical animal studies and human clinical outcomes. Immune responses observed in mice, while informative, often fail to fully recapitulate the complexities of the human immune system, leading to numerous promising treatments faltering during human trials. To mitigate this risk and enhance the predictive power of their research, the DoriVac team strategically employed cutting-edge human Organ Chip technology. Specifically, they utilized a human lymph node-on-a-chip (human LN Chip), a sophisticated microfluidic system developed by the Wyss Institute that meticulously simulates key aspects of the human immune system in vitro. This advanced platform, significantly advanced by co-first author Min Wen Ku and co-corresponding author Dr. Girija Goyal, Director of Bioinspired Therapeutics at the Wyss Institute, provided an unprecedented opportunity to assess DoriVac’s efficacy in a human-relevant context. In this innovative system, the SARS-CoV-2 HR2 DoriVac vaccine demonstrated remarkable activity, effectively activating human dendritic cells (DCs) and significantly boosting their production of inflammatory cytokines—critical signaling molecules that orchestrate immune responses—when compared to origami-free components. Furthermore, the DoriVac vaccine led to a notable increase in the numbers of CD4+ and CD8+ T cells, which are crucial for helper and cytotoxic functions, respectively, both vital for protective immunity. These findings provide compelling evidence for the platform’s potential for direct translation to human use. Dr. Donald Ingber, a co-corresponding author on the study and a leading figure in the Organ Chip field, emphasized the profound implications of this approach: "The predictive capabilities of human LN Chips gave us an ideal testing ground for DoriVac vaccines and the induced, antigen-specific immune cell profiles and activities very likely reflect those that would occur in human recipients of the vaccines. This convergence of technologies enabled us to dramatically raise the chances of success for a new class of vaccines and create a new testbed for future vaccine developments." Dr. Ingber, who also holds positions as the Judah Folkman Professor of Vascular Biology at Harvard Medical School and Boston Children’s Hospital, and the Hansjörg Wyss Professor of Biologically Inspired Engineering at Harvard John A. Paulson School of Engineering and Applied Sciences, underscored the strategic advantage of this human-centric preclinical testing. Head-to-Head with mRNA: A Promising Comparison To further validate DoriVac’s potential, the researchers conducted a direct head-to-head comparison with established mRNA vaccine technologies. Led by Dr. Zeng and co-author Qiancheng Xiong, the team evaluated a DoriVac vaccine presenting the full SARS-CoV-2 spike protein against commercially available Moderna and Pfizer/BioNTech mRNA lipid nanoparticle (LNP) vaccines that encode the identical spike protein. Utilizing a standard booster approach in mouse models, both vaccine types elicited comparably strong antiviral T cell and antibody-producing B cell responses. This critical finding underscored DoriVac’s capacity to generate an immune response on par with the gold-standard mRNA vaccines for COVID-19. However, the DoriVac platform demonstrated distinct and significant advantages beyond immunological equivalence. Dr. Shih highlighted these crucial differences: "This underscored DoriVac’s potential as a DNA nanotechnology-enabled, self-adjuvanted vaccine platform. But DoriVac vaccines have a number of other advantages: they don’t have the same cold-chain requirements as mRNA-LNP vaccines do and thus could be distributed much more effectively, especially in under-resourced regions; and they could overcome some of the enormous manufacturing complexities of LNP-formulated vaccines, to name two major ones." The inherent stability of DNA origami structures means DoriVac vaccines are significantly easier to store and transport, eliminating the prohibitive cold-chain logistics that complicate global distribution of mRNA vaccines. Furthermore, the manufacturing process, while novel, is anticipated to be less complex and more scalable than that for LNP-formulated mRNA vaccines. Recent studies conducted at DoriNano have also provided initial data suggesting a promising safety profile for the DoriVac platform, adding another layer of confidence to its future prospects. Broader Implications and Future Outlook The development of the DoriVac platform represents more than just a new vaccine technology; it signifies a potential paradigm shift in global health equity and pandemic preparedness. The elimination of stringent cold-chain requirements addresses one of the most significant barriers to vaccine access in low- and middle-income countries, where specialized freezers and reliable electricity are often scarce. This could democratize vaccine distribution, ensuring that life-saving immunizations can reach even the most remote populations, a critical step towards achieving universal health coverage. Moreover, the DoriVac platform’s inherent flexibility and "unprecedented control over vaccine composition" offer immense advantages for rapid adaptation to emerging pathogens and evolving variants. Its ability to program immune recognition at a molecular level suggests that future DoriVac vaccines could be designed with enhanced precision, potentially leading to broader and more durable protection against a wider range of infectious agents. The groundwork laid by targeting conserved HR2 regions across multiple viruses (SARS-CoV-2, HIV, Ebola) demonstrates a strategic move towards pan-viral vaccine concepts, which could revolutionize our approach to future pandemics by offering broadly protective shots. The commercialization efforts spearheaded by DoriNano, co-founded by Dr. Zeng, reflect strong confidence in the platform’s translational potential. This move signals the beginning of a journey to bring DoriVac from laboratory innovation to clinical reality, attracting further investment and accelerating the path towards human trials. The continued use of human Organ Chip technology, as championed by Dr. Ingber’s team, will likely play a pivotal role in de-risking these clinical developments, providing a more reliable bridge between preclinical discoveries and human patient outcomes, thereby potentially reducing the high failure rates typically associated with vaccine development. This groundbreaking research was made possible through the generous support of various institutions and funding bodies, including the Director’s Fund and Validation Project program of the Wyss Institute; the Claudia Adams Barr Program at DFCI; the National Institutes of Health (U54 grant CA244726-01); the US-Japan CRDF global fund (grant R-202105-67765); the National Research Foundation of Korea (grants MSIT, RS-2024-00463774, RS-2023-00275456); the Intramural Research Program of the Korea Institute of Science and Technology (KIST); and the Bill and Melinda Gates Foundation (INV-002274). The collaborative spirit and interdisciplinary expertise of the researchers involved—including Sylvie Bernier, Hawa Dembele, Giorgia Isinelli, Tal Gilboa, Zoe Swank, Su Hyun Seok, Anjali Rajwar, Amanda Jiang, Yunhao Zhai, LaTonya Williams, Caleb Hellman, Chris Wintersinger, Amanda Graveline, Andyna Vernet, Melinda Sanchez, Sarai Bardales, Georgia Tomaras, Ju Hee Ryu, and Ick Chan Kwon—were instrumental in bringing this significant scientific advancement to fruition. As the world continues to grapple with existing and emergent infectious threats, the DoriVac platform offers a beacon of hope for a future characterized by more resilient, accessible, and effective vaccine solutions. Post navigation This common vaccine cuts heart risk nearly in half in new study
